23:09 , May 8, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
10:57 , May 7, 2019 |  BioCentury  |  Finance

Confo's €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
00:01 , Apr 30, 2019 |  BioCentury  |  Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
01:54 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
20:28 , Feb 6, 2019 |  BC Extra  |  Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
17:51 , Feb 6, 2019 |  BC Extra  |  Company News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:57 , Jan 17, 2019 |  BC Week In Review  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
23:26 , Jan 15, 2019 |  BC Extra  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
22:48 , Dec 20, 2018 |  BC Extra  |  Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

Exosome therapy company Evox Therapeutics Ltd. (Oxford, U.K.) appointed Edwin Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion Biotherapeutics Ltd. (London, U.K.) and Achilles Therapeutics Ltd. (Stevenage,...